Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Promising data presented on phase 2 trial drug for superficial bladder cancer
December 12th, 2004
Spectrum Pharmaceuticals, Inc. (SPPI) announced encouraging efficacy and safety data from the ongoing multi-center phase 2 trial of EOquin as a single agent in patients with recurrent superficial bladder cancer refractory to at least one prior treatment regimen. The data were presented at the Chemotherapy Foundation Symposium. The abstract, entitled "Intravesical EOquin in the Treatment of Superficial Bladder Cancer," and additional clinical data were presented by J. Alfred Witjes from the University Medical Center Nijmegen, the Netherlands. As of early November, 36 patients (of which 28 were evaluable for efficacy and safety) have been enrolled in this phase 2...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
